

Curriculum Vitae

Full name: Chi-chiu MOK

Consultant and chief of Division of Rheumatology, Department of Medicine,
Tuen Mun Hospital, Hong Kong

Educational background & professional experience

Chi-Chiu Mok is consultant rheumatologist and adjunct teaching professor of the Chinese University of Hong Kong.

An active researcher, Dr. Mok is the first author of more than 200 papers in a number of medical and Rheumatology journals that include the Annals of the Rheumatic Diseases, Nature Review Rheumatology, Arthritis and Rheumatology, Rheumatology (Oxford), and Arthritis Care & Research. Dr. Mok is also the principal investigator of more than 10 phase II/III global trials investigating the safety and efficacy of novel biological agents in various rheumatic diseases.

Dr. Mok is currently the senior associate editor of the International Journal of Rheumatic Diseases and an editorial member of more than 10 medical journals that include the Journal of Rheumatology, Lupus, Current Rheumatology Review, Open Orthopedic Journal and Immunology and Immunogenetic Insights.

Dr. Mok is a Past President of the Hong Kong Society of Rheumatology. He is the founder editor of the Journal of Clinical Rheumatology and Immunology, the official publication of the Hong Kong Society of Rheumatology.

Research Interests

Systemic lupus erythematosus, lupus nephritis
Glucocorticoid induced osteoporosis
Clinical registries of inflammatory arthritis and lupus
Clinical management guidelines for inflammatory arthritis and SLE

Publications

1. Mok CC, Soliman S, Ho LY, Mohamed FA, Mohamed FI, Mohan C. Urinary angiotensin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis. *Arthritis Research and Therapy* 2018 Jan 11;20(1):6
2. Mok CC, Ho LY, Tse SM, Chan KL. Prevalence of remission and its effect on organ damage and quality of life in Chinese patients with systemic lupus erythematosus. *Annals of the Rheumatic Diseases* 2017;76(8):1420-1425
3. Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomized controlled trial and long-term follow-up. *Annals of the Rheumatic Diseases* 2016;75(1) 30-6
4. Mok CC, Ding HH, Kharboutli M, Mohan C. Axl, sTNFR2, ferritin and IGFBP-2 as biomarkers in systemic lupus erythematosus. *Arthritis Care and Research* 2016;68(9):1303-1309
5. Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. *Arthritis Care and Research* 2016;68(9):1295-1302